Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody[1] that acts as an immunomodulator.[2][3]

The drug was developed by Genentech/Roche.

References

  1. ^ Kol A, Terwisscha van Scheltinga A, Pool M, Gerdes C, de Vries E, de Jong S (July 2017). "ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells". Oncotarget. 8 (28): 45432–45446. doi:10.18632/oncotarget.17139. PMC 5542198. PMID 28467975.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Imgatuzumab, American Medical Association.